No speedy nasal rollout for Oxford/AstraZeneca’s Covid-19 jab after PhI flop
Oxford/AstraZeneca’s nasal spray vaccine performed poorly in an early-stage study, squashing hopes for a quick advancement of the duo’s original formulation via an inoculation at SARS-CoV-2’s entryway.
A small study at one site in the UK revealed a bleak outlook for a nasal version of one of the top-administered Covid-19 vaccines in the world, behind breakouts Pfizer/BioNTech and Moderna. The Phase I study included 30 patients who hadn’t previously received a Covid-19 jab and 12 patients who tested the nasal vaccine as a booster.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
